CenterBook Partners’s AtriCure ATRC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-8,530
Closed -$239K – 882
2026
Q2
$239K Buy
+8,530
New +$240K 0.01% 657
2024
Q1
– Sell
-6,055
Closed -$216K – 383
2023
Q4
$216K Sell
6,055
-11,534
-66% -$429K 0.03% 374
2023
Q3
$770K Buy
+17,589
New +$858K 0.1% 272
2023
Q2
– Sell
-5,193
Closed -$215K – 414
2023
Q1
$215K Sell
5,193
-10,607
-67% -$440K 0.03% 370
2022
Q4
$701K Buy
15,800
+8,913
+129% +$372K 0.12% 246
2022
Q3
$269K Buy
+6,887
New +$315K 0.05% 346

Other funds holding ATRC

CenterBook Partners's ATRC Position: Q3 2026 in Review

CenterBook Partners sold out of AtriCure (ATRC) in Q3 2026, closing a stake of 8,530 shares — an estimated $239K sold.

CenterBook Partners first reported a position in ATRC in Q3 2022 and held it in 6 quarters. The position peaked at $770K in Q3 2023. 221 funds tracked by Wall St. Rank hold ATRC as of Q3 2026.

  • CenterBook Partners reported no remaining AtriCure position as of Q3 2026 after selling out during the quarter.
  • CenterBook Partners sold 8,530 AtriCure shares in Q3 2026, an estimated $239K.
  • CenterBook Partners first reported a position in AtriCure in Q3 2022 and held it in 6 quarters.
  • CenterBook Partners's AtriCure position peaked at $770K in Q3 2023.
  • 221 funds tracked by Wall St. Rank held AtriCure as of Q3 2026.

Based on CenterBook Partners's 13F filing for Q3 2026, filed 2 Nov 2026.